Noxopharm Ltd (ASX:NOX) has enrolled and dosed the first patient in its Phase 1 CEP-2 sarcoma trial at the prestigious City of Hope Cancer Center in California.
The influential City of Hope Cancer Center is ranked as one of the most world-renowned cancer hospitals in the USA, according to the US News and World Report.
It is consistently ranked as a top cancer treatment centre in the US and is also a founding member of the National Comprehensive Cancer Network, a non-profit alliance of 21 US cancer centres that publishes clinical practice guidelines for cancer treatment.
City of Hope Cancer Center CEP-2 principal investigator Dr Mark Agulnik said: “We are delighted to have dosed the first patient in the CEP-2 trial. The study investigates the use of Veyonda® in combination with the chemotherapy drug doxorubicin for the treatment of approximately 30 patients with soft tissue sarcoma, which is an aggressive cancer in urgent need of new treatment options.”
First safety results soon
NOX continues to recruit patients for the trial with a view to releasing first safety results once the initial patient cohort has finished the first cycle of combination therapy.
The list of top-ranked cancer hospitals investigating NOX’s flagship Veyonda treatment continues to grow, and the company plans to open further US trial sites in due course.
“Noxopharm is a young and agile Australian biotech company that has managed to attract the depth of talent and experience needed to work with prestigious US institutions such as City of Hope for the CEP-2 study, along with MD Anderson Cancer Center and Beverly Hills Cancer Center for our DARRT program,” Noxopharm CEO Dr Gisela Mautner said.
"We look forward to adding additional world-renowned study sites in the near future.”
About the CEP-2 Trial
CEP-2 is a Phase 1, open-label, dose-escalation and dose-expansion study of Veyonda® administered to cohorts of patients being treated with doxorubicin for the treatment of metastatic soft tissue sarcoma.
Around 30 patients in the United States with a range of soft tissue sarcomas are being enrolled to be treated with the Veyonda and doxorubicin combination as a first-line treatment.
A number of major sites are participating in the CEP-2 trial. The first, the City of Hope Cancer Center in Los Angeles, has commenced treatment, with other sites to be activated shortly.
The CEP program is based on pre-clinical and clinical findings that Veyonda enhances the anti-cancer effect of a number of standard chemotherapeutic agents. The CEP-2 study builds on the findings from CEP-1, as published in the peer-reviewed journal Current Therapeutic Research in April 2021.
About Noxopharm
Noxopharm Ltd (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and inflammation. Veyonda is the company’s first pipe-line drug candidate currently in Phase 1 and 2 clinical trials.